# Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer

> **NCT05383079** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 36 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer
- MCRPC
- Prostate Cancer

## Interventions

- **DRUG:** Lutetium-177 PSMA-I&T
- **DRUG:** Radium-223

## Key facts

- **NCT ID:** NCT05383079
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-13
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05383079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05383079, "Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05383079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*